Go Pro
→ A letter from Shannon Stansberry (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
$124.92
$118.54
$67.09
▼
$148.83
$10.90B1.031.08 million shs1.24 million shs
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$341.12
$339.70
$130.50
▼
$382.54
$10.06B0.53594,653 shs488,442 shs
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$467.32
$516.48
$290.00
▼
$615.00
$10.80B-1.01372,170 shs795,230 shs
uniQure N.V. stock logo
QURE
uniQure
$43.63
$37.49
$8.73
▼
$71.50
$3.03B0.931.51 million shs1.69 million shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
0.00%-0.62%-13.64%+6.22%+73.64%
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
0.00%+1.77%-9.05%+28.22%+117.30%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
0.00%-14.18%-11.51%-9.03%+54.65%
uniQure N.V. stock logo
QURE
uniQure
0.00%+11.96%+4.35%+128.07%+218.70%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
$124.92
$118.54
$67.09
▼
$148.83
$10.90B1.031.08 million shs1.24 million shs
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$341.12
$339.70
$130.50
▼
$382.54
$10.06B0.53594,653 shs488,442 shs
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$467.32
$516.48
$290.00
▼
$615.00
$10.80B-1.01372,170 shs795,230 shs
uniQure N.V. stock logo
QURE
uniQure
$43.63
$37.49
$8.73
▼
$71.50
$3.03B0.931.51 million shs1.69 million shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
0.00%-0.62%-13.64%+6.22%+73.64%
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
0.00%+1.77%-9.05%+28.22%+117.30%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
0.00%-14.18%-11.51%-9.03%+54.65%
uniQure N.V. stock logo
QURE
uniQure
0.00%+11.96%+4.35%+128.07%+218.70%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
2.80
Moderate Buy$156.5025.28% Upside
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
2.83
Moderate Buy$360.675.73% Upside
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
2.72
Moderate Buy$688.2047.27% Upside
uniQure N.V. stock logo
QURE
uniQure
2.71
Moderate Buy$65.0048.98% Upside

Current Analyst Ratings Breakdown

Latest QURE, MDGL, ABVX, and KRYS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/31/2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
7/31/2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
7/31/2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$962.00
7/30/2026
uniQure N.V. stock logo
QURE
uniQure
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$65.00 ➝ $60.00
7/30/2026
uniQure N.V. stock logo
QURE
uniQure
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$60.00 ➝ $75.00
7/29/2026
uniQure N.V. stock logo
QURE
uniQure
Wolfe Research logo
Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradePeer Perform ➝ Outperform$65.00
7/29/2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
Canaccord Genuity Group Inc. logo
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$578.00 ➝ $587.00
7/27/2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight$685.00
7/27/2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight$685.00
7/24/2026
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$180.00
7/17/2026
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
(Data available from 8/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
N/AN/AN/AN/A$6.57 per shareN/A
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$389.13M25.84$7.29 per share46.79$42.06 per share8.11
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$958.40M11.26N/AN/A$26.54 per share17.61
uniQure N.V. stock logo
QURE
uniQure
$16.10M187.99N/AN/A$3.19 per share13.68
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
-$380.27M-$5.21N/AN/AN/AN/A-99.02%-70.26%9/21/2026 (Estimated)
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$204.83M$7.4845.6036.68N/A53.92%19.25%17.62%8/3/2026 (Estimated)
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-$288.28M-$12.89N/A52.98N/A-25.32%-56.65%-25.53%N/A
uniQure N.V. stock logo
QURE
uniQure
-$198.97M-$4.01N/AN/AN/A-1,350.73%-111.96%-29.01%N/A

Latest QURE, MDGL, ABVX, and KRYS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/3/2026Q2 2026
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$1.73N/AN/AN/A$121.81 millionN/A
7/30/2026Q2 2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-$2.68-$1.99+$0.69-$1.99$352.13 million$364.25 million
7/29/2026Q2 2026
uniQure N.V. stock logo
QURE
uniQure
-$0.8223-$1.22-$0.3977-$1.22$5.45 million$5.84 million
5/22/2026Q1 2026
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
-$0.9359-$0.71+$0.2259-$0.71$0.40 million$1.56 million
5/6/2026Q1 2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-$3.61-$3.25+$0.36-$3.25$301.05 million$311.34 million
5/5/2026Q1 2026
uniQure N.V. stock logo
QURE
uniQure
-$0.88-$0.85+$0.03-$0.85$5.21 million$3.56 million
5/4/2026Q1 2026
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$1.45$1.83+$0.38$1.83$112.11 million$116.36 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
N/AN/AN/AN/AN/A
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
N/AN/AN/AN/AN/A
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
N/AN/AN/AN/AN/A
uniQure N.V. stock logo
QURE
uniQure
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
N/A
8.25
8.25
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
N/A
9.46
9.06
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
0.65
3.20
2.94
uniQure N.V. stock logo
QURE
uniQure
0.15
10.01
10.01

Institutional Ownership

CompanyInstitutional Ownership
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
47.91%
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
86.29%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
98.50%
uniQure N.V. stock logo
QURE
uniQure
78.83%

Insider Ownership

CompanyInsider Ownership
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
N/A
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
13.10%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
17.60%
uniQure N.V. stock logo
QURE
uniQure
4.65%
CompanyEmployeesShares OutstandingFree FloatOptionable
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
6187.25 millionN/ANot Optionable
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
21029.48 million25.62 millionOptionable
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
9023.10 million19.04 millionOptionable
uniQure N.V. stock logo
QURE
uniQure
50069.37 million66.14 millionOptionable

Recent News About These Companies

HC Wainwright Issues Negative Estimate for uniQure Earnings
 |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30937163
Equities Analysts Issue Forecasts for uniQure Q3 Earnings
 |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/equities-analysts-issue-forecasts-for-uniqure-q3-earnings-2026-08-03/
uniQure (NASDAQ:QURE) Price Target Raised to $75.00
August 2 at 2:36 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30935610
uniQure (NASDAQ:QURE) Downgraded to "Sell" Rating by Wall Street Zen
August 1 at 1:49 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30933587
uniQure (NASDAQ:QURE) Stock Rating Lowered by Wall Street Zen
August 1 at 1:47 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/uniqure-nasdaqqure-stock-rating-lowered-by-wall-street-zen-2026-08-01/
uniQure: 'Hold' AMT-130 U-Turn By FDA For HD Could Possibly Alter Course
July 31 at 5:51 PM  |  seekingalpha.comhttps://seekingalpha.com/article/4928942-uniqure-hold-amt-130-u-turn-by-fda-for-hd-could-possibly-alter-course?utm_source=marketbeat.com&utm_medium=referral&feed_item_type=article?source=MarketBeat
Barclays Keeps Their Buy Rating on uniQure (QURE)
July 31 at 12:49 PM  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/QURE/pressreleases/3571191/barclays-keeps-their-buy-rating-on-uniqure-qure/
UniQure welcomes possible adcomm for Huntington’s asset as regulatory ‘jitters’ spread through biopharma
July 31 at 12:49 PM  |  biospace.comB
QURE Q2 Earnings Miss Estimates on Higher Costs, Revenues Rise Y/Y
July 30, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2964752/qure-q2-earnings-miss-estimates-on-higher-costs-revenues-rise-y-y?cid=cs-stocknewsapi-ft-analyst_blog|earnings_article-2964752
Wells Fargo & Company Issues Positive Forecast for uniQure (NASDAQ:QURE) Stock Price
July 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/wells-fargo-company-issues-positive-forecast-for-uniqure-nasdaqqure-stock-price-2026-07-30/
uniQure N.V. (QURE) Q2 2026 Earnings
July 30, 2026  |  247wallst.comhttps://247wallst.com/cards/uniqure-n-v-q2-2026-earnings-qure-01kypscy2phm6k6d1zs7kb1j4j
UniQure outlines AMT-130 BLA this quarter, supported by cash runway into 2030
July 30, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4620738-uniqure-outlines-amtminus-130-bla-this-quarter-supported-by-cash-runway-into-2030
AdCom expected for uniQure’s Huntington’s gene therapy, chief medical officer says
July 30, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/adcom-expected-uniqure-huntington-gene-154916146.html
Stempoint Capital LP Has $1.28 Million Stock Position in uniQure N.V. $QURE
July 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-stempoint-capital-lp-has-128-million-stock-position-in-uniqure-nv-qure-2026-07-30/
uniQure N.V. (QURE) Q2 2026 Earnings Call Transcript
July 29, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4927181-uniqure-n-v-qure-q2-2026-earnings-call-transcript
uniQure Q2 Earnings Call Highlights
July 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/uniqure-q2-earnings-call-highlights-2026-07-29/
uniQure (NASDAQ:QURE) Trading Up 7.9% - What's Next?
July 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/uniqure-nasdaqqure-trading-up-79-whats-next-2026-07-29/
uniQure (NASDAQ:QURE) Releases Quarterly Earnings Results, Misses Expectations By $0.40 EPS
July 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/uniqure-nasdaqqure-releases-quarterly-earnings-results-misses-expectations-by-040-eps-2026-07-29/
uniQure (QURE) Reports Q2 Loss, Misses Revenue Estimates
July 29, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2962819/uniqure-qure-reports-q2-loss-misses-revenue-estimates?cid=cs-stocknewsapi-ft-tale_of_the_tape|yseop_template_4-2962819
uniQure Q2 Revenue Rises to $5.8 Million as AMT-130 Filing Nears
July 29, 2026  |  quiverquant.comQ
uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update
July 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/29/3335112/0/en/uniqure-announces-second-quarter-2026-financial-results-and-provides-company-update.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
A semiconductor wafer with the SK hynix logo displayed inside a manufacturing fabrication facility.
SK Hynix’s Nasdaq Listing Could Reset the AI Memory Trade
By Thomas Hughes | July 7, 2026
Rocket Lab Electron rocket on coastal launch pad with company logo overlay, symbolizing space tech integration strategy.
Rocket Lab’s Stock Drop Comes With a Bullish Twist
By Ryan Hasson | July 10, 2026
Two Very Large Crude Carriers (VLLCs) sailing side by side on open ocean waters, viewed from above.
Strait of Hormuz Tensions Spike Tanker Trade: These 2 Stocks Are Set to Benefit
By Dan Schmidt | July 19, 2026
A digital illustration of a glowing AI brain connected to circuit pathways against a city skyline backdrop.
2 AI Stocks That Could Benefit as AI Moves Beyond the Data Center
By Thomas Hughes | July 5, 2026
Abivax logo displayed in a laboratory setting with a microscope, vials, and lab equipment on a counter.
Abivax: Wall Street Catches Up to the Data
By Chris Markoch | July 7, 2026
Abivax stock logo

Abivax NASDAQ:ABVX

$124.92 0.00 (0.00%)
Closing price 07/31/2026 04:00 PM Eastern
Extended Trading
$123.88 -1.04 (-0.83%)
As of 07/31/2026 07:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

Krystal Biotech stock logo

Krystal Biotech NASDAQ:KRYS

$341.12 0.00 (0.00%)
Closing price 07/31/2026 04:00 PM Eastern
Extended Trading
$339.40 -1.72 (-0.50%)
As of 07/31/2026 07:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Madrigal Pharmaceuticals stock logo

Madrigal Pharmaceuticals NASDAQ:MDGL

$467.32 0.00 (0.00%)
Closing price 07/31/2026 04:00 PM Eastern
Extended Trading
$464.98 -2.34 (-0.50%)
As of 07/31/2026 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

uniQure stock logo

uniQure NASDAQ:QURE

$43.63 0.00 (0.00%)
Closing price 07/31/2026 04:00 PM Eastern
Extended Trading
$43.81 +0.18 (+0.41%)
As of 07/31/2026 07:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas